Literature DB >> 31490892

Preoperative Computed Tomography Features of Intrahepatic Cholangiocarcinoma for Predicting Lymph Node Metastasis and Overall Survival.

Yong Zhu1, Yingfan Mao2, Jun Chen3, Yudong Qiu4, Zhongqiu Wang1, Jian He2.   

Abstract

OBJECTIVES: The aims of this study were to compare the difference of computed tomography (CT) features between intrahepatic cholangiocarcinomas (ICCs) with and without lymph node metastasis (LNM) and to construct a nomogram to predict LNM and overall survival preoperatively.
METHODS: Clinicopathological and contrast-enhanced CT features of 63 patients with ICC were analyzed. Multivariate logistic regression analysis was performed to construct a nomogram to predict LNM preoperatively. Survival curves were drawn with the Kaplan-Meier method, and survival difference was compared.
RESULTS: Intrahepatic cholangiocarcinomas with and without LNM differed significantly in clinical symptoms, tumor location, morphologic classification, arterial phase enhancement degree-mean, arterial phase enhancement degree-max, portal venous phase enhancement degree-max, equilibrium phase (EP) enhancement ratio, EP CT value-max, and EP CT value-max/liver. A nomogram based on morphologic classification, EP CT value-max, and EP enhancement ratio was constructed to predict LNM with an area under curve of 0.814 (P < 0.001). Patients with ICC with LNM risk of 0.20 or greater based on the nomogram showed a significantly poorer overall survival than those with LNM risk less than 0.20 (39.5 ± 5.2 vs 51.1 ± 4.7 months).
CONCLUSIONS: Preoperative CT features of ICCs differed significantly between those with and without LNM. Nomogram based on those features could predict LNM and overall survival even better than the N stage.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31490892     DOI: 10.1097/RCT.0000000000000922

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  4 in total

1.  Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma.

Authors:  Elena Panettieri; Harufumi Maki; Bradford J Kim; HyunSeon Christine Kang; Veronica Cox; Eduardo A Vega; Takashi Mizuno; Shubham Pant; Milind Javle; Jean-Nicolas Vauthey; Yoshikuni Kawaguchi
Journal:  Surg Oncol       Date:  2021-12-31       Impact factor: 3.279

2.  Prognostic Value of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma Patients With Clinically Negative Lymph Node Metastasis: A Multi-Center Study From China.

Authors:  Qiao Ke; Lei Wang; Ziguo Lin; Jianying Lou; Shuguo Zheng; Xinyu Bi; Jianming Wang; Wei Guo; Fuyu Li; Jian Wang; Yamin Zheng; Jingdong Li; Shi Cheng; Weiping Zhou; Yongyi Zeng
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

3.  Clinical Staging of Mass-Forming Intrahepatic Cholangiocarcinoma: Computed Tomography Versus Magnetic Resonance Imaging.

Authors:  Yeun-Yoon Kim; Suk-Keu Yeom; Seung Soo Lee; Mi-Suk Park; Hyejung Shin; Sang Hyun Choi; Hyungjin Rhee; Ji Hoon Park; Eun-Suk Cho; Sumi Park
Journal:  Hepatol Commun       Date:  2021-08-24

4.  High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma.

Authors:  Muntinee Lertpanprom; Atit Silsirivanit; Patcharaporn Tippayawat; Tanakorn Proungvitaya; Sittiruk Roytrakul; Siriporn Proungvitaya
Journal:  Front Public Health       Date:  2022-08-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.